
|Articles|February 1, 2005
Iris pigmentation changes monitored with glaucoma therapy
Uppsala, Sweden—Adjunctive latanoprost (Xalatan, Pfizer) therapy for open-angle glaucoma is safe and effective, based on the results of a 5-year assessment of the drug. The mean decrease in IOP was 25% of the baseline IOP and this was sustained without any treatment change in 70% of eyes.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
Last year in glaucoma at EnVision Summit 2025
3
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
4
Looking back at the 2025 EnVision Summit
5




























